Inactivated vaccinia virus effective against advanced cancers alone or combined with immune checkpoint inhibitors

September 6, 2017, American Association for Cancer Research

Modified vaccinia virus Ankara (MVA), a poxvirus, was found to be safe when administered in an inactivated form in mice, and delivering it into the tumor in addition to systemic delivery of an immune checkpoint inhibitor yielded synergistic antitumor effects in mice with large tumors and those with multiple tumors, according to data presented at the Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, held Sept. 6-9.

"Immune checkpoint blockade therapy, such as anti-CTLA-4 and anti-PD1/PD-L1 antibodies, has been approved for the treatment of many advanced or ; however, the response rate to this form of therapy alone is still quite low," said Liang Deng, MD, PhD, dermatologist/investigator and Assistant Member in the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York (MSKCC).

One of the reasons for failure to respond or for developing resistance to immune checkpoint inhibitors is that there is paucity of infiltrating in these tumors, making them "cold tumors," Deng explained. "Microbial-based cancer immunotherapy has the potential to turn 'cold tumors' to 'hot tumors,'" she added.

Microbes, such as the MVA tested in this study, can be detected by the host immune system as "foreign" and can induce the production of certain immune substances including interferons (IFN), proinflammatory cytokines and chemokines. "The production of these factors in the tumors by the immune and cells leads to the activation of immune cells and the generation and recruitment of tumor-specific T cells, which can destroy tumor cells," noted Deng. "Therefore, it is important to develop potent microbial-based agents to 'light the fire' in the tumor microenvironment."

Deng and collagues found that the combination of intratumoral injection of heat-inactivated MVA (iMVA) and immune checkpoint inhibitors led to efficient eradication of large, established tumors and distant non-injected tumors in mice. They showed that the antitumor activity was possible because iMVA is a potent inducer of type I IFN and proinflammatory immune mediators. Intratumoral injection of iMVA also altered the immunosuppressive tumor microenvironment and generated antitumor CD4+ and CD8+ T cells, which could be amplified by the addition of immune checkpoint blockade. The researchers published these findings in Science Immunology in May 2017.

Current oncolytic viruses including talimogene laherparepvec (T-VEC), an engineered herpes simplex virus that has been approved by the U.S. Food and Drug Administration for the treatment of advanced melanoma, are replication competent, said Deng. These infectious agents are generally handled in infection-controlled rooms, and adverse events have been reported in patients when the viruses are administered at high doses or if the patients are immune-compromised. It is not known whether viral replication is necessary for the antitumor effects of the DNA virus when delivered intratumorally. To test this, the researchers compared the antitumor efficacy of live oncolytic vaccinia virus (which can replicate) with its heat-inactivated counterpart (which cannot replicate) in mice. They found that the heat-inactivated oncolytic vaccinia virus induced higher numbers of activated CD4+ and CD8+ T cells than the live virus. This meant that the inactivated form of the virus is both safe and effective.

"We were pleasantly surprised that inactivated oncolytic vaccinia virus works better than live virus," noted Deng. "These results tell us that in order for viral-based therapy to work, it has to engage the host immune system through induction of innate immunity and activation of tumor antigen-presenting dendritic cells," she added.

"Our results support the intratumoral delivery of inactivated vaccinia as a safe and effective either alone or in combination with immune checkpoint blockade antibodies," said Deng.

"We anticipate that iMVA could be used in several clinical settings, including patients with metastatic cancers that are resistant to immune checkpoint blockade, or those with metastatic cancers that are initially responsive to immune checkpoint blockade and later develop resistance, or it could be used as a combinatory therapy with immune blockade," she noted. "We plan to bring these viral-based products into clinical trials in the coming years." This work is the result of a collaboration of several investigators at MSKCC, including Deng, Stewart Shuman, MD, PhD, Jedd D. Wolchok, MD, PhD, and Taha Merghoub, PhD.

A limitation of the study is that although heat-inactivated MVA induces IFN and proinflammatory immune mediators in human melanoma cells and , the antitumor efficacy data were obtained in murine tumor models, Deng said. "Human clinical trials will be necessary to address whether this approach works in the treatment of human cancers," she added.

Explore further: Immune checkpoint blockade improves antitumor vaccine response in mouse glioblastoma model

More information: Peihong Dai et al. Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells, Science Immunology (2017). DOI: 10.1126/sciimmunol.aal1713

Related Stories

Immune checkpoint blockade improves antitumor vaccine response in mouse glioblastoma model

July 7, 2016
Glioblastoma has an extremely poor prognosis, and there is a critical need for new therapies to treat the disease. Immunotherapy helps the immune system destroy cancer cells, and recent clinical evaluation of an immune cell-based ...

Checkpoint inhibitors fire up different types of T cells to attack tumors

August 10, 2017
Cancer immunotherapies that block two different checkpoints on T cells launch immune attacks on cancer by expanding distinct types of T cell that infiltrate tumors, researchers from The University of Texas MD Anderson Cancer ...

Researchers show how a targeted drug overcomes suppressive immune cells

November 9, 2016
A Ludwig Cancer Research study shows that an experimental drug currently in clinical trials can reverse the effects of troublesome cells that prevent the body's immune system from attacking tumors. The researchers also establish ...

DNA sensor plays critical role in cancer immunotherapy via response to unexpected DNA form

August 24, 2017
UT Southwestern Medical Center researchers report for the first time that tumors stressed by cancer immunotherapy release their mitochondrial DNA into nearby immune cells, triggering a host alert system.

Clinical trial uses a genetically engineered virus to fight cancer

August 15, 2017
Sanford Health is the first site in the United States to launch a clinical trial using a genetically-engineered virus that aims to destroy therapy-resistant tumors.

Concurrent treatment with OX40- and PD1-targeted cancer immunotherapies may be detrimental

August 28, 2017
Concurrent administration of the T-cell stimulating anti-OX40 antibody and the immune checkpoint inhibitor anti-PD1 antibody attenuated the effect of anti-OX40 and resulted in poor treatment outcomes in mice.

Recommended for you

Researchers use a molecular Trojan horse to deliver chemotherapeutic drug to cancer cells

February 23, 2018
A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

Study tracks evolutionary transition to destructive cancer

February 23, 2018
Evolution describes how all living forms cope with challenges in their environment, as they struggle to persevere against formidable odds. Mutation and selective pressure—cornerstones of Darwin's theory—are the means ...

Lab-grown 'mini tumours' could personalise cancer treatment

February 23, 2018
Testing cancer drugs on miniature replicas of a patient's tumour could help doctors tailor treatment, according to new research.

An under-the-radar immune cell shows potential in fight against cancer

February 23, 2018
One of the rarest of immune cells, unknown to scientists a decade ago, might prove to be a potent weapon in stopping cancer from spreading in the body, according to new research from the University of British Columbia.

Putting black skin cancer to sleep—for good

February 22, 2018
An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes ...

Cancer risk associated with key epigenetic changes occurring through normal aging process

February 22, 2018
Some scientists have hypothesized that tumor-promoting changes in cells during cancer development—particularly an epigenetic change involving DNA methylation—arise from rogue cells escaping a natural cell deterioration ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.